Peter Chedraui1, Gustavo S Escobar2, Faustino R Pérez-López3, Giulia Palla4, Magdalena Montt-Guevara4, Elena Cecchi4, Andrea R Genazzani4, Tommaso Simoncini4. 1. Institute of Biomedicine, Research Area for Women's Health, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador. Electronic address: peter.chedraui@cu.ucsg.edu.ec. 2. Institute of Biomedicine, Research Area for Women's Health, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador. 3. Department of Obstetrics and Gynecology, Facultad de Medicina, Lozano Blesa University Hospital, Universidad de Zaragoza, Spain. 4. Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Italy.
Abstract
BACKGROUND: Prevalence of the metabolic syndrome (METS) increases after the menopause; nevertheless, concomitant vascular, inflammatory and endothelial changes have not been completely elucidated. OBJECTIVE: To measure serum markers of angiogenesis, inflammation and endothelial function in postmenopausal women screened for the METS. METHODS: Serum of 100 postmenopausal women was analyzed for angiopoietin-2, interleukin-8 (IL-8), soluble FAS ligand (sFASL), interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α), soluble CD40 ligand (sCD40L), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator (uPA). Comparisons were made in accordance to the presence or not of the METS and each of its components. Modified Adult Treatment Panel III criteria were used to define the METS. RESULTS: Women with the METS (n=57) had similar age and time since menopause as compared to those without the syndrome (n=43). In general, women with the METS displayed a trend for higher levels of the analyzed markers. Nevertheless, only IL-6 levels were found to be significantly higher and uPA levels significantly lower among METS women as compared to those without the syndrome. When analyte levels were compared as to presenting or not each of the diagnostic features of the METS, it was found that IL-6 levels were higher among women with abdominal obesity, low HDL-C and high triglyceride levels. Women with low HDL-C and high triglyceride levels presented significantly lower uPA levels and those with high glucose and low HDL-C displayed significantly higher sCD40L levels. CONCLUSION: Postmenopausal women with the METS in this sample displayed higher IL-6 (inflammation) and lower uPA levels (endothelial dysfunction). These were mainly related to metabolic and lipid abnormalities. More research is warranted in this regard.
BACKGROUND: Prevalence of the metabolic syndrome (METS) increases after the menopause; nevertheless, concomitant vascular, inflammatory and endothelial changes have not been completely elucidated. OBJECTIVE: To measure serum markers of angiogenesis, inflammation and endothelial function in postmenopausal women screened for the METS. METHODS: Serum of 100 postmenopausal women was analyzed for angiopoietin-2, interleukin-8 (IL-8), soluble FAS ligand (sFASL), interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α), soluble CD40 ligand (sCD40L), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator (uPA). Comparisons were made in accordance to the presence or not of the METS and each of its components. Modified Adult Treatment Panel III criteria were used to define the METS. RESULTS:Women with the METS (n=57) had similar age and time since menopause as compared to those without the syndrome (n=43). In general, women with the METS displayed a trend for higher levels of the analyzed markers. Nevertheless, only IL-6 levels were found to be significantly higher and uPA levels significantly lower among METS women as compared to those without the syndrome. When analyte levels were compared as to presenting or not each of the diagnostic features of the METS, it was found that IL-6 levels were higher among women with abdominal obesity, low HDL-C and high triglyceride levels. Women with low HDL-C and high triglyceride levels presented significantly lower uPA levels and those with high glucose and low HDL-C displayed significantly higher sCD40L levels. CONCLUSION: Postmenopausal women with the METS in this sample displayed higher IL-6 (inflammation) and lower uPA levels (endothelial dysfunction). These were mainly related to metabolic and lipid abnormalities. More research is warranted in this regard.
Authors: P Chedraui; F R Pérez-López; G S Escobar; J A Espinoza-Caicedo; M Montt-Guevara; A R Genazzani; T Simoncini Journal: J Endocrinol Invest Date: 2016-02-22 Impact factor: 4.256
Authors: Krithika Srikanthan; Andrew Feyh; Haresh Visweshwar; Joseph I Shapiro; Komal Sodhi Journal: Int J Med Sci Date: 2016-01-01 Impact factor: 3.738
Authors: Philip D Chilibeck; Faustino R Pérez-López; Peter F Bodary; Eun Seok Kang; Justin Y Jeon Journal: Int J Endocrinol Date: 2014-03-03 Impact factor: 3.257